This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on prevention and treatment — if they keep current with developments in drug therapy.
Get full access to this article
View all access options for this article.
References
1.
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA.2001; 285: 2486–97.
2.
American Heart Association.2002 Heart and Stroke Statistical Update. Dallas, TX.
3.
CastelliW.P.Lipids, risk factors and ischaemic heart disease. Atherosclerosis.1996; 124(suppl):S1–S9.
4.
RossR.Atherosclerosis: An inflammatory disease. N Engl J Med.1999; 340: 115–26.
5.
ShishehborM.H., BhattD.L.Inflammation and atherosclerosis. Curr Atheroscler Rep.2004; 6: 131–9.
6.
SzmitkoP.E., WangC.H., WeiselR.D.New markers for inflammation and endothelial cell activation: Part I. Circulation.2003; 108: 1917–23.
7.
VermaS., KuliszewskiM.A., LiS.H.C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation.2004; 109: 2058–67.
8.
MunfordR.S.Statins and the acute-phase response. N Engl J Med.2001; 344: 2016–8.
9.
LiuzzoG., LuigiM.B., GallimoreJ.R.The prognostic value of C-reactive protein in severe unstable angina. N Engl J Med.1994; 331: 417–24.
10.
ThompsonS.G., KienastP., PykeS.D.Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med.1995; 332: 635–41.
11.
KullerL.H., TracyR.P., ShatenJ.Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol.1996; 144: 537–47.
12.
RidkerP.M., BuringJ.E., ShihJ.Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation.1998; 98: 731–3.
13.
RidkerP.M., HennekensC.H., BuringJ.E.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med.2000; 342: 836–43.
14.
RidkerP.M., RifaiN., RoseL.Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med.2002; 347: 1557–65.
15.
CaoJ.J., ThachC., ManolioT.A.C-reactive protein, carotid intima-media thickness and incidence of ischemic stroke in the elderly. The Cardiovascular Health Study. Circulation.2003; 98: 839–44.
16.
DaneshJ., WheelerJ.G., HirschfieldG.M.C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med.2004; 350: 1387–97.
17.
RidkerP.M., RifaiN., PfefferM.A.Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation.1998; 98: 839–44.
18.
RidkerP.M., RifaiN., PfefferM.A.Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation.1999; 100: 230–5.
19.
RidkerP.M., RifaiN., ClearfieldM.Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med.2001; 344: 1959–65.
20.
RidkerP.M., CushmanM., StampferM.J.Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med.1997; 336: 973–9.
21.
RidkerP.M., StampferM.J., RifaiN.Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA.2001; 285: 2481–5.
22.
PearsonT.A., MensahG.A., AlexanderR.W.Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation.2003; 107: 499–511.
23.
TchernofA., NolanA., SitesC.K.Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation.2002; 105: 564–9.
24.
MilaniR.V., LavieC.J., MehraM.R.Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol.2004; 43: 1056–61.
25.
VolpatoS., PahorM., FerrucciL.Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitor-1 in well-functioning older adults: The Health, Aging, and Body Composition study. Circulation.2004; 109: 607–12.
26.
ZairisM.N., AmbroseJ.A., LyrasA.G.C-reactive protein, moderate alcohol consumption, and long term prognosis after successful coronary stenting: Four years from the GENERATION study. Heart.2004; 90: 419–24.
27.
RidkerP.M.Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation.2003; 107: 363–9.
28.
JialalI., SteinD., BalisD.Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation.2001; 103: 1933–5.
29.
GrundyS.M., VegaG.L., McGovernM.E.Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med.2002; 162: 1568–76.
30.
MalikJ., MelenovskyV., WichterleD.Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial-FAT). Cardiovascular Research.2001; 52: 290–8.
31.
GagneC., BaysH., WeissS.R.Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with prmary hypercholesterolemia. Am J Cardiol.2002; 90: 1084–91.
32.
HaffnerS.M., GreenbergA.S., WestonW.M.Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation.2002; 106: 679–84.
33.
FengD., TracyR.P., LipinskaI.Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombol.2000; 9: 37–41.
34.
IkonomidisI., AndreottiF., EconomouE.Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation.1999; 100: 793–8.
35.
LincoffA.M., KereiakesD.J., MascelliM.A.Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation.2001; 104: 163–7.
36.
BuffonA., LiuzzoG., BiasucciL.Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol.1999; 34: 1512–21.
37.
ChewD.P., BhattD.L., RobbinsM.A.Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol.2001; 88: 672–4.
38.
CushmanM., LegaultC., Barrett-ConnorE.Effect of postmenopausal hormones on inflammation-sensitive proteins: The postmenopausal estrogen/progestin interventions (PEPI) study. Circulation.1999; 100: 717–22.
39.
RidkerP.M., HennekensC.H., RifaiN.Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation.1999; 100: 713–6.
40.
VongpatanasinW., TuncelM., ZhongyunW.Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol.2003; 41: 1358–63.
41.
RidkerP.M., CookN.Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation.2004; 109: 1955–9.
